Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Micelas poliméricas orientadas de forma activa para administración de fármacos y génica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190411001
Publicado:
29/04/2019
Caducidad:
29/04/2020
Resumen:
Un centro español de investigación biomédica en red ha desarrollado nuevas micelas como vectores no virales para la administración de fármacos (en particular para la administración de siRNA o RNA pequeños de interferencia) en células cancerosas. Las nuevas nanopartículas o micelas son capaces de administrar a las células compuestos de diferente naturaleza (medicamentos, genes u otros compuestos) para fines terapéuticos o no terapéuticos. Las micelas permiten administrar oligonucleótidos (OGN) a las células de forma efectiva y segura y están compuestas por copolímeros en bloque biodegradables, biocompatibles y de baja inmunogenicidad y por un componente capaz de condensar siRNA y mejorar la eficiencia de transfección y actividad biológica sin efectos tóxicos en las células. Esta composición también permite que las micelas adopten un sistema de autoensamblaje especial en un disolvente no polar. El centro busca socios industriales con el fin de establecer acuerdos de licencia, investigación o cooperación técnica.

Details

Tittle:
Actively targeted polymeric micelles for drug and gene delivery
Summary:
A Spanish biomedical research networking center has developed innovative micelles as non-viral vectors for drug delivery (in particular for siRNA - small interfering RNA delivery) into cancer cells. They are looking to establish license, research cooperation or technical cooperation agreements.
Description:
This Spanish research networking center gathers some of the most important Spanish research groups in biomedicine, located in more than 100 institutions like universities, hospitals, and technological centers distributed around the country.

In recent years, nanomedicine has substantially evolved aiming to achieve great advances in diseases treatment and diagnosis. Among the wide range of nanometric vehicles used for drug delivery polymeric micelles have been proved as efficient nanosized (approximately 20 to 200 nm) polymeric self-assembly systems for encapsulating drugs and gene (gene therapy).
In this context, gene therapy has appeared as a promising alternative for an effective and more specific treatment of cancer and other complex diseases with an important genetic background. However, the in vivo delivery of oligonucleotides (OGN) has precluded the clinical use of gene-based therapies mainly due to its vulnerability to enzymatic blood degradation, poor cellular uptake, and rapid renal clearance. Therefore, the greatest challenge for a successful clinical application of gene therapy relies on the development of vectors able to condensate negatively charged OGN and to effectively deliver them into the cytoplasm and/or nucleus of target cells.
Nowadays, viral vectors are still considered the most efficient, being the most commonly used for gene transfer in both pre-clinical and clinical research, however, the well-known drawbacks related with viral-based vectors such as their immunogenicity, mutagenesis, carcinogenesis, limited cargo loading, and time-consuming/high-cost procedures, boosted the development of safer vehicles using a wide range of lipids and polymers (non-viral vectors).
In this sense, the research center has developed new and innovative nanoparticles (micelles) as non-viral vectors which are able to deliver into cells compounds of different nature (drug, gene, other compounds), to be used for therapeutic and non-therapeutic purposes.
The center is looking to establish license, research cooperation or technical cooperation agreements with industrial partners.
Advantages and Innovations:
These innovative nanoparticles are able to deliver into cells compounds of different nature (drug, gene, other compounds), and they can be used for therapeutic (as cancer) and non-therapeutic purposes.
These new micelles allow the delivery of oligonucleotides (OGN) in an effective and safety mode into the cells.
The micelles composition comprises biodegradable, biocompatible and low immunogenicity block copolymers and a component able to condense siRNA (small interfering RNA) and improve its transfection efficiency and biological activity without toxic cell effects. This composition also allows the micelles to adopt a special self-assembly system in a non-polar solvent.
A pharmaceutical composition can be obtained in aqueous media with a therapeutically effective amount of a drug-loaded polymeric micelle together with pharmaceutically acceptable excipients and/or carriers (use as medicament).
Multifunctional delivery systems can also be developed. Those systems allow the simultaneous treatment with two or more therapeutic agents, as well as the traceability of the delivered compounds and cells when the delivered compound is a cell marker (e.g. dye)
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority European patent application filed
International extension PCT filed

Partner sought

Type and Role of Partner Sought:
Patent ready for licensing-out.

The research center is seeking industrial partners, either Biotech or Pharma, to:

- enter into preclinical R-Y-D collaboration (in vitro and/or in vivo drug testing).

- Further development until clinical proof-of-concept.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06006006 Nanomateriales biológicos
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos
06001009 Terapia genética - ADN